Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Active Motif to Collaborate on FPGA-Based Analysis of Sequencing Data

NEW YORK (GenomeWeb News) – Invitrogen and Active Motif said today that they will collaborate in exploring the use of field programmable gate array technology for analyzing next-generation sequencing data.
Active Motif markets TimeLogic's biocomputing systems, which couple an FPGA accelerator with optimized genomics algorithms to rapidly compare novel sequences to databases of well-characterized genes.
The alliance is aimed at exploring “ways in which [Active Motif’s] technology can speed the processing of data directly from next-generation sequencing instruments, and to assess the physical requirements — such as power consumption, cooling, data transfer, and space constraints — that an optimal computational solution for research and clinical teams would require,” Joe Fernandez, CEO of Carlsbad, Calif.-based Active Motif, said in a statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.